OncoPrecision, a New York, NY and Córdoba, Argentina-based Patient Micro Avatar technology company, raised $3.3m in Seed funding.
The round, closed in April, was led by SOSV’s IndieBio, GRIDX, New York Ventures (the venture capital arm of the State of New York), Creative Ventures, Fundación Para el Progreso de la Medicina (a diagnostics lab where the company’s Argentine lab is based), exited biotech and non-biotech founders, as well as strategic angel investors and family offices.
The company, has raised a total of $4.2m to date, intends to use the funds to further develop its technology.
Founded in late 2020 by Dr. Gastón Soria, Dr. Candelaria Llorens, Dr. Gerardo Gatti and repeat founder Tarek Zaki, OncoPrecision provides a high-throughput platform that focuses on obtaining patient-derived cells from biopsies and recreating the tumor microenvironment by combining them with proprietary engineered cells that seek to “trick” the cancer cells to act as though they were still in the patient’s body. With this combination of patient-derived cells and engineered cells, OncoPrecision creates miniaturized Patient Micro Avatars which are then dosed with single and combinatory drugs simultaneously. Each Avatar’s response to treatment is then analyzed at a high resolution using flow cytometry and machine learning models that accurately track the response of the distinct cell populations within each Avatar.
The company is currently performing clinical validation studies with multiple cancer centers for its Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia models and is advancing in the development of its technology for additional hematologic and solid cancers. OncoPrecision is also in active drug development collaborations.
FinSMEs
01/11/2022